Thomas G. McGinn, MD, MPH System Executive Vice President, CommonSpirit Health
On Tuesday, April 13, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) jointly announced a recommendation to pause administration of the Janssen/Johnson & Johnson (J&J) vaccine as it undergoes further investigation for rare blood clotting events.
Publish date:
Tuesday, May 25, 2021CommonSpirit Health released financial results for its fiscal year 2024 first quarter ended Sept. 30. The results reflected strong volume growth, offset by rising costs which are also impacting many other health care providers.
Read More Additional information about CommonSpirit Health Released FY2024 First Quarter ResultsDr. Alisahah Jackson, President of CommonSpirit's Lloyd Dean Institute for Humankindness and Health Justice, discusses initiatives impacting health equity.
Read More Additional information about Podcast: A Conversation About Eliminating Health InequitiesCommonSpirit’s Chief Strategy Officer, Sheri Shapiro, joins the Healthcare Is Hard podcast to discuss how she’s leading the organization's diverse markets and service lines into the future.
Read More Additional information about Podcast: CSO Sheri Shapiro Discusses Healthcare Strategy